Compare · GLP-1 agonist
Ecnoglutide vs Survodutide
Both are glp-1 agonist compounds. Here's how they line up on the evidence — graded the same way.
| Ecnoglutide | Survodutide | |
|---|---|---|
| Evidence | Preliminary human | Preliminary human |
| Class | GLP-1 agonist | GLP-1 agonist |
| Summary | A long-acting, cAMP-biased GLP-1 receptor agonist approved in China for type 2 diabetes and weight management, with genuine peer-reviewed Phase 3 data that is still confined to Chinese populations and not FDA-approved. | An investigational GLP-1/glucagon dual agonist with solid placebo-controlled Phase 2 trials and one positive Phase 3 topline, but no approval and no peer-reviewed Phase 3 data. |
| Full profile → | Full profile → |
Ecnoglutide
Ecnoglutide (development code XW003) is an injectable drug for type 2 diabetes and weight loss that belongs to the same broad GLP-1 receptor agonist family as semaglutide. It stands out for two reasons: its developer engineered it to be "cAMP-biased," a real and characterized pharmacological…
Survodutide
Survodutide (development code BI 456906) is an investigational injectable drug being studied for obesity, fatty-liver disease, and type 2 diabetes. It has a stronger human evidence base than most peptides sold online, including several well-run placebo-controlled trials and one positive Phase 3…